Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01506349 · ClinicalTrials.gov registry record · NA
Assessing Neurocognitive Effects of Gluten Exposure
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01506349 is a NA study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT01506349, a NA study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Many patients with celiac disease complain of neurocognitive symptoms such as mental confusion, grogginess, difficulty with concentration and forgetfulness after exposure to gluten. However, there is little data on any possible association between impaired cognitive function and gluten intake in celiac disease. The investigators predict that patients with celiac disease, when exposed to gluten, will experience neurocognitive symptoms such as confusion, forgetfulness and difficulty concentrating. The goals of this study are to determine the prevalence of neurocognitive symptoms after exposure to gluten in patients with celiac disease and to characterize the nature of these symptoms both in terms of their duration and severity.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT gluten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01506349
The ClinicalTrials.gov registry entry for NCT01506349 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01506349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01506349 about?
NCT01506349 is a clinical study titled "Assessing Neurocognitive Effects of Gluten Exposure". Many patients with celiac disease complain of neurocognitive symptoms such as mental confusion, grogginess, difficulty with concentration and forgetfulness after exposure to gluten. However, there is little data on any possible association between impaired cognitive function and gluten intake in cel...
What is the current status of trial NCT01506349?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2015-06. Estimated completion is 2018-03.
What interventions are being tested in trial NCT01506349?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), gluten (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01506349?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.